Moreover, if our hypothesis proves true, the distinct molecular mechanisms underlying dyskinesia between PARKIN patients and late-onset PD patients could be relevant for devising precision medicine strategies for parkin patients. This evidence concerns the gene PRKN and drug-induced dyskinesia.